World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
43
Citations
7054
World Ranking
4847
National Ranking
405

Aymen Al-Shamkhani publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Aymen Al-Shamkhani sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 121 publications — 7th percentile

7% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Aymen Al-Shamkhani D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Aymen Al-Shamkhani sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 43 D-Index — 2nd percentile

2% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

Aymen Al-Shamkhani is affiliated with the University of Southampton in the United Kingdom. Their research focus spans immunology and microbiology as well as medicine, with significant contributions across related subfields including immunology, oncology, radiology, nuclear medicine and imaging, epidemiology, and molecular biology.

The scientist's work addresses key topics within immunotherapy and immune responses, immune cell function and interaction, monoclonal and polyclonal antibodies research, cancer immunotherapy and biomarkers, T-cell and B-cell immunology, CAR-T cell therapy research, and nonmelanoma skin cancer studies.

Frequent publication venues for their research include the Journal for ImmunoTherapy of Cancer, Clinical Cancer Research, bioRxiv (Cold Spring Harbor Laboratory), Cancer Research, and JCI Insight.

Among their recent papers are the following:

  • NOX4 Inhibition Potentiates Immunotherapy by Overcoming Cancer-Associated Fibroblast-Mediated CD8 T-cell Exclusion from Tumors, 2020, Cancer Research
  • CD8+CD103+ tissue-resident memory T cells convey reduced protective immunity in cutaneous squamous cell carcinoma, 2021, Journal for ImmunoTherapy of Cancer
  • Domain binding and isotype dictate the activity of anti-human OX40 antibodies, 2020, Journal for ImmunoTherapy of Cancer
  • Peptide: MHC-based DNA vaccination strategy to activate natural killer cells by targeting killer cell immunoglobulin-like receptors, 2021, Journal for ImmunoTherapy of Cancer
  • Agonist Antibodies for Cancer Immunotherapy: History, Hopes, and Challenges, 2023, Clinical Cancer Research

Collaborators frequently working with Aymen Al-Shamkhani include Mark S. Cragg, Jinny Kim, Tatyana Inzhelevskaya, C. Ian Mockridge, and Martin J. Glennie.

Best Publications

  • Viral infection switches non-plasmacytoid dendritic cells into high interferon producers

    Sandra S Diebold;Maria Montoya;Hermann Unger;Lena Alexopoulou

  • NOX4 Inhibition Potentiates Immunotherapy by Overcoming Cancer-Associated Fibroblast-Mediated CD8 T-cell Exclusion from Tumors

    Kirsty Ford;Christopher J Hanley;Massimiliano Mellone;Cedric Szyndralewiez

  • Combination CTLA-4 Blockade and 4-1BB Activation Enhances Tumor Rejection by Increasing T-Cell Infiltration, Proliferation, and Cytokine Production

    Michael A. Curran;Myoungjoo Kim;Welby Montalvo;Aymen Al-Shamkhani

  • CD134L expression on dendritic cells in the mesenteric lymph nodes drives colitis in T cell-restored SCID mice.

    V Malmström;D Shipton;B Singh;A Al-Shamkhani

  • The immunobiology of CD27 and OX40 and their potential as targets for cancer immunotherapy

    Sarah L. Buchan;Anne Rogel;Aymen Al-Shamkhani

  • Interaction with FcγRIIB Is Critical for the Agonistic Activity of Anti-CD40 Monoclonal Antibody

    Ann L. White;H. T. Claude Chan;Ali Roghanian;Ruth R. French

  • Expression and costimulatory effects of the TNF receptor superfamily members CD134 (OX40) and CD137 (4-1BB), and their role in the generation of anti-tumor immune responses.

    Vadim Y. Taraban;Tania F. Rowley;Lyn O'Brien;H. T. Claude Chan

  • Systemic 4-1BB activation induces a novel T cell phenotype driven by high expression of Eomesodermin

    Michael A. Curran;Theresa L. Geiger;Welby Montalvo;Myoungjoo Kim

  • Conformation of the Human Immunoglobulin G2 Hinge Imparts Superagonistic Properties to Immunostimulatory Anticancer Antibodies

    Ann L. White;H.T. Claude Chan;Ruth R. French;Jane E. Willoughby

  • Eradication of lymphoma by CD8 T cells following anti-CD40 monoclonal antibody therapy is critically dependent on CD27 costimulation

    Ruth R. French;Vadim Y. Taraban;Graham R. Crowther;Tania F. Rowley

  • Cutting Edge: A Critical Role for CD70 in CD8 T Cell Priming by CD40-Licensed APCs

    Vadim Y. Taraban;Tania F. Rowley;Aymen Al-Shamkhani

  • Analysis of the oligomeric requirement for signaling by CD40 using soluble multimeric forms of its ligand, CD154

    Linsey E. Haswell;Martin J. Glennie;Aymen Al-Shamkhani

  • OX40 is differentially expressed on activated rat and mouse T cells and is the sole receptor for the OX40 ligand.

    A al-Shamkhani;M L Birkeland;M Puklavec;M H Brown

  • The Death Receptor 3–TNF-like protein 1A pathway drives adverse bone pathology in inflammatory arthritis

    Melanie Jane Bull;Anwen Siân Williams;Zarabeth Mecklenburgh;Claudia Jane Calder

  • Stimulation by soluble CD70 promotes strong primary and secondary CD8+ cytotoxic T cell responses in vivo.

    Tania F. Rowley;Aymen Al-Shamkhani

  • Antibodies to Costimulatory Receptor 4-1BB Enhance Anti-tumor Immunity via T Regulatory Cell Depletion and Promotion of CD8 T Cell Effector Function.

    Sarah L. Buchan;Lang Dou;Marcus Remer;Steven G. Booth

  • Dysregulation of Antiviral Function of CD8+ T Cells in the Chronic Obstructive Pulmonary Disease Lung. Role of the PD-1–PD-L1 Axis

    Richard T. McKendry;C. Mirella Spalluto;Hannah Burke;Ben Nicholas

  • A single subset of dendritic cells controls the cytokine bias of natural killer T cell responses to diverse glycolipid antigens.

    Pooja Arora;Andres Baena;Karl O.A. Yu;Neeraj K. Saini

  • The TNF-Family Ligand TL1A and Its Receptor DR3 Promote T Cell–Mediated Allergic Immunopathology by Enhancing Differentiation and Pathogenicity of IL-9–Producing T Cells

    Arianne C. Richard;Cuiyan Tan;Eric T. Hawley;Julio Gomez-Rodriguez

  • PD-1 Blockade and CD27 Stimulation Activate Distinct Transcriptional Programs That Synergize for CD8+ T-Cell-Driven Antitumor Immunity.

    Sarah L. Buchan;Mohannad Fallatah;Stephen M. Thirdborough;Vadim Y. Taraban

  • antibody therapy is critically dependent on CD27 costimulation Eradication of lymphoma by CD8 T cells following anti-CD40 monoclonal

    Alison L. Tutt;Aymen Al-Shamkhani;Martin J. Glennie;Ruth R. French

Frequent Co-Authors

Martin J. Glennie
Martin J. Glennie University of Southampton
Mark S. Cragg
Mark S. Cragg University of Southampton
Eugene Healy
Eugene Healy University of Southampton
Peter Johnson
Peter Johnson University of Southampton
Edward Chung Yern Wang
Edward Chung Yern Wang Cardiff University
James P. Allison
James P. Allison The University of Texas MD Anderson Cancer Center
Richard M. Siegel
Richard M. Siegel National Institutes of Health
J. Sjef Verbeek
J. Sjef Verbeek Leiden University Medical Center
Tim Elliott
Tim Elliott University of Southampton
Salim I. Khakoo
Salim I. Khakoo University of Southampton

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in Immunology, related healthcare fields such as nursing practitioner programs offer valuable career alternatives. When exploring these options, it’s important to consider program flexibility; many students seek the easiest nurse practitioner program to balance studies with other commitments without compromising quality.

Mental health is another growing specialty, and aspiring professionals should carefully select programs known for strong clinical training. The top pmhnp programs highlight institutions with superb clinical placement rates, ensuring hands-on experience essential for success.

Cost is often a deciding factor; prospective students can find affordable pathways through the cheapest psychiatric nurse practitioner programs, which help reduce financial barriers to advanced education.

Finally, understanding potential earnings after graduation is crucial for career planning. Resources outlining how much a DNP makes provide insights into salary expectations across states, helping guide informed decisions about where to study and work.

Best Scientists Citing Aymen Al-Shamkhani

Trending Scientists